NYSEAMERICAN:OCX - OncoCyte Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$4.48 -0.31 (-6.47 %)
(As of 05/24/2019 04:00 PM ET)
Previous Close$4.79
Today's Range$4.45 - $4.89
52-Week Range$1.16 - $6.92
Volume93,882 shs
Average Volume898,626 shs
Market Capitalization$232.84 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer. The company was founded in 2009 and is based in Alameda, California. OncoCyte Corporation is a subsidiary of BioTime, Inc.

Receive OCX News and Ratings via Email

Sign-up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:OCX
CUSIPN/A
Phone(510) 775-0515

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees12
Market Cap$232.84 million
Next Earnings Date8/13/2019 (Estimated)
OptionableNot Optionable

OncoCyte (NYSEAMERICAN:OCX) Frequently Asked Questions

What is OncoCyte's stock symbol?

OncoCyte trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OCX."

How were OncoCyte's earnings last quarter?

OncoCyte Corp (NYSEAMERICAN:OCX) posted its quarterly earnings data on Tuesday, May, 14th. The biotechnology company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.01. View OncoCyte's Earnings History.

When is OncoCyte's next earnings date?

OncoCyte is scheduled to release their next quarterly earnings announcement on Tuesday, August 13th 2019. View Earnings Estimates for OncoCyte.

What price target have analysts set for OCX?

5 Wall Street analysts have issued twelve-month price targets for OncoCyte's shares. Their forecasts range from $6.00 to $8.00. On average, they anticipate OncoCyte's share price to reach $7.00 in the next year. This suggests a possible upside of 56.3% from the stock's current price. View Analyst Price Targets for OncoCyte.

What is the consensus analysts' recommendation for OncoCyte?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OncoCyte.

Has OncoCyte been receiving favorable news coverage?

News stories about OCX stock have trended positive on Saturday, according to InfoTrie. The research firm ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. OncoCyte earned a coverage optimism score of 2.3 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days.

Are investors shorting OncoCyte?

OncoCyte saw a increase in short interest in the month of April. As of April 30th, there was short interest totalling 828,304 shares, an increase of 6.1% from the April 15th total of 780,426 shares. Based on an average trading volume of 126,270 shares, the days-to-cover ratio is presently 6.6 days. Approximately 2.8% of the company's shares are short sold. View OncoCyte's Current Options Chain.

Who are some of OncoCyte's key competitors?

What other stocks do shareholders of OncoCyte own?

Who are OncoCyte's key executives?

OncoCyte's management team includes the folowing people:
  • Mr. William Annett, Pres, CEO & Director (Age 65)
  • Mr. Mitchell S. Levine, Chief Financial Officer
  • Dr. Lyndal K. Hesterberg, Chief Scientific Officer
  • Mr. Albert P. Parker II, Chief Operating Officer
  • Dr. Michael D. West, Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc. (Age 66)

Who are OncoCyte's major shareholders?

OncoCyte's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Emerald Mutual Fund Advisers Trust (4.79%), Schonfeld Strategic Advisors LLC (1.67%), Renaissance Technologies LLC (0.26%), BlackRock Inc. (0.24%), Northern Trust Corp (0.11%) and JPMorgan Chase & Co. (0.09%). View Institutional Ownership Trends for OncoCyte.

Which major investors are buying OncoCyte stock?

OCX stock was purchased by a variety of institutional investors in the last quarter, including Emerald Mutual Fund Advisers Trust, Schonfeld Strategic Advisors LLC, Renaissance Technologies LLC, BlackRock Inc., JPMorgan Chase & Co., Northern Trust Corp, Spark Investment Management LLC and Virtu Financial LLC. View Insider Buying and Selling for OncoCyte.

How do I buy shares of OncoCyte?

Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is OncoCyte's stock price today?

One share of OCX stock can currently be purchased for approximately $4.48.

How big of a company is OncoCyte?

OncoCyte has a market capitalization of $232.84 million. OncoCyte employs 12 workers across the globe.

What is OncoCyte's official website?

The official website for OncoCyte is http://www.oncocyte.com/.

How can I contact OncoCyte?

OncoCyte's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at (510) 775-0515.


MarketBeat Community Rating for OncoCyte (NYSEAMERICAN OCX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  125 (Vote Outperform)
Underperform Votes:  100 (Vote Underperform)
Total Votes:  225
MarketBeat's community ratings are surveys of what our community members think about OncoCyte and other stocks. Vote "Outperform" if you believe OCX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OCX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/25/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel